Loading
Life sciences · Journal article
iScience · October 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Obesity promotes chronic low-grade inflammation through metabolic stress and activation of the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome. The effects of caloric restriction on this pathway in humans are poorly understood; therefore, we evaluated the impact of a 6-month hypocaloric dietary intervention in 45 adults with obesity by assessing the metabolic, inflammatory, oxidative stress, and inflammasome-related markers in peripheral blood mononuclear cells. Weight loss improved metabolic parameters, reduced oxidative stress, and decreased the expression of nuclear factor κB (NF-κB), NLRP3, apoptosis-associated speck-like protein containing a CARD (ASC), and pro-caspase-1, while there tended to be a reduction of active caspase-1. These changes were accompanied by lower circulating interleukin (IL)-1β (IL-1β) and IL-18 levels, suggesting systemic attenuation of inflammasome activity. Baseline adiposity and insulin resistance influenced the magnitude of the response to dietary intervention. These findings support caloric restriction as a strategy to mitigate obesity-associated immunometabolic dysfunction and identify the redox-inflammasome axis as a potential therapeutic target.